complex biological products such as regenerative medicine therapies, through grants to institutions of higher education and nonprofit organizations and other appropriate mechanisms, for each of fiscal years 2020 through 2029, $50,000,000. (D) For support for the Commissioner of Food and Drugs to engage experts, such as through the formation and operation of public-private partnerships or other appropriate collaborative efforts, to advance the development and delivery of individualized human gene therapy products: (i) For fiscal year 2020, $50,000,000. (ii) For each of fiscal years 2021 through 2029, $10,000,000. (E) For support for inspections and enforcement activities across the Food and Drug Administration, including foreign and domestic facility inspections across products, for each of fiscal years 2020 through 2029, $82,500,000. (F) For support for activities of the Food and Drug Administration related to customs and border protection to provide improvements to technologies, inspection capacity, and international mail facilities in which the Food and Drug Administration operates, for each of fiscal years 2020 through 2029, $25,000,000. (G) To further advance the development of a coordinated postmarket surveillance system for all medical products, including drugs, biological products, and devices, linked to electronic health records in furtherance of the Food and Drug Administration’s postmarket surveillance capabilities: (i) For fiscal year 2020, $100,000,000. (ii) For each of fiscal years 2021 through 2029, $50,000,000. (H) For support for Food and Drug Administration activities to keep pace with the projected product development of regenerative therapies, including human somatic cellular and gene therapies, for each of fiscal years 2020 through 2029, $25,000,000. (I) For support for the development of non-opioid pharmacological therapies as alternatives for opioids, for each of fiscal years 2020 through 2029, $3,500,000. (J) For carrying out section 714A of the Federal Food, Drug, and Cosmetic Act (21